By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Arbitrators have sided with Exiqon, allowing it to market locked nucleic acid-based LNA amidites and LNA oligonucleotides to the pharmaceutical market, the Danish firm announced today.

The decision by an arbitration court ends proceedings initiated by Exiqon last year against Santaris Pharma in a dispute over the LNA products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.